Comparison of 5-fluorouracil pharmacokinetics following intraperitoneal and intravenous administration using in vivo 19F magnetic resonance spectroscopy.

Intrahepatic pharmacokinetic studies of 5-Fluorouracil (5 FU) metabolism following intravenous and intraperitoneal administration have been undertaken in four patients using in vivo 19F nuclear magnetic resonance spectroscopy. Following intravenous administration, 5 FU decayed with "half times" ranging from 5 to 17 min. There was considerable variation of 5 FU pharmacokinetics between patients following intraperitoneal administration. Peritoneal contamination by infused 5 FU was considered to be a significant problem in one patient. A technique for providing superficial signal suppression was therefore investigated and its efficacy for excluding signal from the peritoneal space has been demonstrated. Owing to the potential for contamination from peritoneal 5 FU, the accumulation of fluoro-beta-alanine (FBAL) is a more reliable indicator of drug catabolism than the measurement of unlocalized "hepatic" 5 FU. Rapid intrahepatic catabolism of 5 FU to FBAL was demonstrated in all patients. However, there was greater pharmacokinetic variation following intraperitoneal administration than following intravenous administration. Therapeutic implications of intravenous compared with intraperitoneal administration of 5 FU are discussed.

[1]  M O Leach,et al.  Conformal NMR spectroscopy: Accurate localization to noncuboidal volumes with optimum SNR , 1989, Magnetic resonance in medicine.

[2]  R. Martino,et al.  Direct 19f NMR spectroscopic observation of 5‐fluorouracil metabolism in the isolated perfused mouse liver model , 1988, NMR in Biomedicine.

[3]  R. Herrmann,et al.  Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. , 1988, Cancer research.

[4]  N. Kemeny,et al.  Tumor and liver drug uptake following hepatic artery and portal vein infusion. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W Wolf,et al.  Fluorine-19 NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy. , 1987, Magnetic resonance imaging.

[6]  Speyer Jl The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies. , 1985 .

[7]  Dedrick Rl Theoretical and experimental bases of intraperitoneal chemotherapy. , 1985 .

[8]  D. Machin,et al.  A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer , 1985, The British journal of surgery.

[9]  J. Griffiths,et al.  5-fluorouracil metabolism monitored in vivo by 19F NMR. , 1984, British Journal of Cancer.

[10]  L. Prosnitz,et al.  Radiotherapy (First of two parts) , 1983 .

[11]  H. Slocum,et al.  Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture. , 1979, Cancer research.

[12]  S. Carter Editorial: Large-bowel cancer-The current status of treatment. , 1976, Journal of the National Cancer Institute.